ClinicalTrials.gg
CompletedNCT03088254Updated Jul 6, 2018

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

A Phase 3 interventional study of Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg) and Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo) in Dyslipidemia With Hypertension, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 12 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-07-06.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2016, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing telmisartan in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Telmisartan · Dyslipidemias.

Enrollment
3rd of 11
126 · median 63
Started
2016
with 1 other
Phase 3
3 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
Jeil Pharmaceutical Co., Ltd.

Among the 11 studies testing telmisartan in Dyslipidemias, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 3, and was the 5th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing telmisartan in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing telmisartan in Dyslipidemias as a file.
02

Study summary

To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.

03

Conditions studied

  • Dyslipidemia With Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dyslipidemia with hypertesion
  • msSBP \< 180 mmHg
  • msDBP \< 110 mmHg
  • LDL-C ≤ 250 mg/dL
  • Triglycerides \< 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • At Visit 3, BP difference SBP ≥20mmHg or DBP ≥10mmHg
  • CK normal range ≥ 2 times
  • Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)
  • or ALT ≥ 2 times
  • Uncontrolled diabetes mellitus (≥9%)
  • \< 30 mL/min/1.73m\^2
  • K > 5.5 mEq/L
  • Other exclusion applied
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Group I

    Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks

    Drug: Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)

  • Active comparator
    Group II

    Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks

    Drug: Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)

  • Active comparator
    Group III

    Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks

    Drug: Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

Interventions

  • Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks

  • DrugGroup II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)

    Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks

  • DrugGroup III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

    Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks

06

What researchers measure

Primary outcomes

  1. change of LDL-C

    Time frame: baseline and 8 weeks

  2. change of msSBP

    Time frame: baseline and 8 weeks

07

Study locations

12 sites
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Pusan, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • KyungHee University Hospital at Gangdong
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • SoonChunHyang University Hospital, Seoul
    Seoul, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Hong SJ, Jeong HS, Cho JM, Chang K, Pyun WB, Ahn Y, Hyon MS, Kang WC, Lee JH, Kim HS. Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clin Ther. 2019 Feb;41(2):233-248.e9. doi: 10.1016/j.clinthera.2018.12.008. Epub 2019 Jan 18. PubMed 30665829 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jul 2017, 10 months.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 10 months is below that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 23, 2017
StartActual
Sep 20, 2016
Primary completionActual
Jul 31, 2017
CompletionActual
Dec 4, 2017
Last update
Jul 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03088254
Responsible party
Sponsor
First posted
Mar 23, 2017
Start date
Sep 20, 2016
Primary completion
Jul 31, 2017
Completion
Dec 4, 2017
Last update
Jul 6, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion